<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461903/" ref="ordinalpos=1121&amp;ncbi_uid=4494678&amp;link_uid=PMC3461903" image-link="/pmc/articles/PMC3461903/figure/F2/" class="imagepopup">Figure 2. Schematic representation of the PDGF/PDGFR <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> (Generated using MetaCore software; GeneGo Inc.)..  From: New molecular insights into peripheral T cell lymphomas. </a></div><br /><div class="p4l_captionBody">Notably, different key points of PDGFR signaling can be the object of pharmacological inhibition. First, PDGFRs can be directly blocked by TKIs. Second, the immediate downstream JAK/STAT pathway, SRC kinase and PI3K can be selectively disrupted. Finally, in cases retaining NF-ÎºB activity (around 30% of PTCL-NOSs), different molecules might be targeted. Adapted with permission from Expert Review of Hematology (59). </div></div>